Movement disorders clinical practice · 2026
Real-World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9-Year Nationwide Analysis in France.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Simonetta-Moreau Marion, Karam Pierre, Forestier Anne, Degos Bertrand
Аннотация
BACKGROUND: Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT-A). Real-world evidence on treatment patterns remains limited.
OBJECTIVE: This nationwide, population-based study aimed to evaluate trends in BoNT-A use in France between 2015 and 2023, using the French National Hospital Discharge Database (Programme de Médicalisation des Systèmes d'Information, PMSI).
METHODS: Patients were classified into four categories (dystonia, tremor, myoclonus, and other abnormal movements), based on International Classification of Diseases, 10th Revision (ICD-10). Annual changes in the number of BoNT-A injections and treated patients were analyzed. Treatment adherence and reinjection intervals were also evaluated.
RESULTS: A total of 51,861 patients received BoNT-A therapy. Dystonia was the predominant indication (44,913; 86.6%). Tremor accounted for 3690 patients (7.1%), other abnormal movements for 2423 (4.7%), and myoclonus for 835 (1.6%). Between 2015 and 2023, BoNT-A injections increased from 49,829 to 53,828 (+8.0%) and treated patients from 20,023 to 21,489 (+7.3%). While dystonia showed minimal growth in patient numbers (+0.6%), tremor and myoclonus increased substantially (+132.1% and +179.7%, respectively). Repeat BoNT-A injections were highest in dystonia, with 71.8% of patients receiving ≥3 injections and 57.9% receiving ≥5 injections in total. Median reinjection intervals ranged from 112 days in dystonia to 133 days in myoclonus.
CONCLUSIONS: Dystonia remains the leading indication for BoNT-A in France, with high treatment adherence. The marked growth in tremor and myoclonus underscores the expanding therapeutic role and diversification of BoNT-A use across hyperkinetic movement disorders.
OBJECTIVE: This nationwide, population-based study aimed to evaluate trends in BoNT-A use in France between 2015 and 2023, using the French National Hospital Discharge Database (Programme de Médicalisation des Systèmes d'Information, PMSI).
METHODS: Patients were classified into four categories (dystonia, tremor, myoclonus, and other abnormal movements), based on International Classification of Diseases, 10th Revision (ICD-10). Annual changes in the number of BoNT-A injections and treated patients were analyzed. Treatment adherence and reinjection intervals were also evaluated.
RESULTS: A total of 51,861 patients received BoNT-A therapy. Dystonia was the predominant indication (44,913; 86.6%). Tremor accounted for 3690 patients (7.1%), other abnormal movements for 2423 (4.7%), and myoclonus for 835 (1.6%). Between 2015 and 2023, BoNT-A injections increased from 49,829 to 53,828 (+8.0%) and treated patients from 20,023 to 21,489 (+7.3%). While dystonia showed minimal growth in patient numbers (+0.6%), tremor and myoclonus increased substantially (+132.1% and +179.7%, respectively). Repeat BoNT-A injections were highest in dystonia, with 71.8% of patients receiving ≥3 injections and 57.9% receiving ≥5 injections in total. Median reinjection intervals ranged from 112 days in dystonia to 133 days in myoclonus.
CONCLUSIONS: Dystonia remains the leading indication for BoNT-A in France, with high treatment adherence. The marked growth in tremor and myoclonus underscores the expanding therapeutic role and diversification of BoNT-A use across hyperkinetic movement disorders.